Evidence map›Paper›PMID 38185937›Full record

ArticleJournal of medical virology2024

Generation and characterization of a humanized ACE2 mouse model to study long-term impacts of SARS-CoV-2 infection.

Chang-Yong Choi, Kundlik Gadhave, Jason Villano, Andrew Pekosz, Xiaobo Mao, Hongpeng Jia

Open access · hybridAbstract read
In one paragraph

Article in Journal of medical virology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 13 citations in OpenAlex.

  1. Long COVID: current research and future directions.Infectious diseases & immunity · 2025
    Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Chang-Yong ChoiDivision of Pediatric Surgery, Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Kundlik GadhaveDepartment of Neurology, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Jason VillanoMolecular and Comparative Pathobiology, The Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
Andrew PekoszDepartment of Molecular Microbiology and Immunology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Xiaobo MaoDepartment of Neurology, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Hongpeng JiaDivision of Pediatric Surgery, Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.ORCID 0000-0001-6783-7532
Johns Hopkins University · US

Funding

'T V ASSESSMENT - MEMORY DISORDERED PATIENTS'P50AG005146 · NIA · JOHNS HOPKINS UNIVERSITY · PI BANDEEN-ROCHE, KAREN J. · 1985 to 2019
$37.6M
Murine Mutagenesis CoreP30NS050274 · NINDS · JOHNS HOPKINS UNIVERSITY · PI KOLODKIN, ALEX L · 2005 to 2020
$10.9M
Mechanism of Pathologic Tau Fibrils Neuron-to-Neuron Transmission and Neuroinflammation in Alzheimer's DiseaseR01AG073291 · NIA · JOHNS HOPKINS UNIVERSITY · PI MAO, XIAOBO · 2021 to 2025
$3.2M
The role of ACE2 in Influenza viral infection mediated immune compromise and subsequent bacterial lung infectionR01AI148446 · NIAID · JOHNS HOPKINS UNIVERSITY · PI JIA, HONGPENG · 2020 to 2024
$2.9M
Understanding the Mechanism of Pathological alpha-Synuclein TransmissionR01NS107318 · NINDS · JOHNS HOPKINS UNIVERSITY · PI MAO, XIAOBO · 2019 to 2023
$2.0M
Supplement to "New ACE2 activator and its prodrug as novel therapeutic regents for inflammatory pulmonary diseases"R21AI149321 · NIAID · JOHNS HOPKINS UNIVERSITY · PI JIA, HONGPENG · 2020 to 2021
$892k
NIAID NIH HHS R01 AI148446NIAID NIH HHS R21 AI149321NIA NIH HHS P50 AG005146NIA NIH HHS R01 AG073291NIH HHS 1R01AI148446-01A1NIH HHS 1R2AI14932101NIH HHS 3R21AI149321-01S1NIH HHS P50 AG05146NIH HHS R01AG073291NIH HHS R01NS107318NINDS NIH HHS P30 NS050274NINDS NIH HHS R01 NS107318
6 · The paper itself

Abstract

Although the COVID-19 pandemic has officially ended, the persistent challenge of long-COVID or post-acute COVID sequelae (PASC) continues to impact societies globally, highlighting the urgent need for ongoing research into its mechanisms and therapeutic approaches. Our team has recently developed a novel humanized ACE2 mouse model (hACE2ki) designed explicitly for long-COVID/PASC research. This model exhibits human ACE2 expression in tissue and cell-specific patterns akin to mouse Ace2. When we exposed young adult hACE2ki mice (6 weeks old) to various SARS-CoV-2 lineages, including WA, Delta, and Omicron, at a dose of 5 × 10

Indexed as

COVID-19Angiotensin-Converting Enzyme 2AnimalsDisease Models, AnimalDisease ProgressionHumansMicePandemicsPost-Acute COVID-19 SyndromeSARS-CoV-2Young AdultAce2 protein, mouseAngiotensin-Converting Enzyme 2Alzheimer's diseasehumanized ACE2 mouse modelimmune responselong-COVIDSARS-CoV-2tau pathology

Identifiers

PMID38185937
PMCPMC10783855
OpenAlexW4390666986

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.